Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon ?-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus.
Ontology highlight
ABSTRACT: The present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such as elderly and/or cirrhotic patients, and to elucidate the factors contributing to a sustained virologic response (SVR).One hundred IFN ineligible patients infected with genotype 1b hepatitis C virus (HCV) were treated. Simeprevir (100 mg) was given orally together with reduced doses of PEG-IFN-? 2a (90 ?g), and ribavirin (200 mg less than the recommended dose).The patients' median age was 70 years, and 70 patients were cirrhotic. Three patients (3%) discontinued treatment due to adverse events. The SVR rate was 64%. Factors that significantly contributed to the SVR included the ?-glutamyl transferase and ?-fetoprotein levels, interleukin- 28B (IL28B) polymorphism status, and the level and reduction of HCV RNA at weeks 2 and 4. The multivariate analysis showed that the IL28B polymorphism status was the only independent factor that predicted the SVR, with a positive predictive value of 77%.Simeprevir-based triple therapy with reduced doses of PEG-IFN and ribavirin was safe and effective for IFN ineligible patients infected with genotype 1b HCV. IL28B polymorphism status was a useful predictor of the SVR.
SUBMITTER: Tamai H
PROVIDER: S-EPMC5491091 | biostudies-literature | 2017 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA